^·sDelta¯f¬r¶Ç¬V¤O¼W15¢H
®Æ¦¨³Ì´cÅÜºØ ¦û¦P¨t¯f¨Ò10¢H
^°ê¯f¬r¾Ç®a³Ìªñ°lÂÜ·s«¬«aª¬¯f¬rDeltaÅܺذò¦]ºtÅܮɡA½T»{¥X·sDelta«á¥NAY.4.2¡A¥¦¥Ø«e¦b^°ê¨³³t¶Ç¼½¡A¤w¦û¥þ°ê©Ò¦³Delta¡u¤À¤ä¡v¯f¨Òªº10%¡C^°ê¥Ø«eªº·s«a½T¶EÓ®×¥HÅܺØDelta¬°¥D¡C±M®aªí¥Ü¡A®Ú¾Úªì¨B¤ÀªR¡A·sÅܺتº¶Ç¬V¤O¦ü¥G¸ûDeltaÅܺذª10%¦Ü15%¡A¥@¬É½Ã¥Í²Õ´¦³¥i¯à±N¥¦¤É¯Å¦Ü¡u¨ü½Õ¬dªºÅܺءv(variant under investigation)¡A¨Ã¤©¥H©R¦W¡C
^°êºû±d®á®æ¬ã¨s©Ò(Wellcome Sanger Institute)ªº·s«a¯f¬r°ò¦]²Õ¾Çp¹º¥D¥ô¤Ú¹p¯S(Jeffrey Barrett)©MÛ´°¤j¾Ç¾Ç°|°ò¦]¬ã¨s©Ò¥D¥ô¤Ú¿c(Francois Balloux)ªí¥Ü¡Aªì¨B¬Ý¨Ó³o´Ú¨ÈÅܺØAY.4.2ªº¶Ç¬V¤O¦ü¥G¤ñDelta(³Ì¥ý¦b¦L«×¥X²{)ìÅܺخ谪¥X10%¦Ü15%¡C¤Ú¿c«ü¥X¡AÕYÀò±oÃÒ¹ê¡AAY.4.2±N¬O¬Ì±¡Ãzµo¥H¨Ó³Ì¨ã¶Ç¬V¤Oªº·s«a¯f¬r®è¡A¦ý¥L±j½Õ²{¶¥¬q¤´¶·ÂÔ·V¡A¡u^°ê¬OӮװߤ@¥H³oºØ¤è¦¡«æ¤Éªº°ê®a¡A§Ú¤´¤£·|±Æ°£¨ä¼W¥[¥u¬O°¸µoªº¤H¤f¨Æ¥ó¡C¡v¤Ú¿c»{¬°¡AAY.4.2¥i¯à³Q´£°ª¦Ü¡u¨ü½Õ¬dªºÅܺءv¯Å§O¡A©¡®É¥@½Ã·|®Ú¾Ú¨ä©R¦W¨t²Î¡A¥H§Æþ¦r¥À¬°AY.4.2¨ú¦W¡C
^°ê¬F©²¨¾¬Ì«Øij±M®a®ü¨U¼w(Andrew Hayward)¼~¼{¡A^°ê½T¶E¡B«¯g¤Î¦º¤`²v§¡¤ñ¤£¤Ö¼Ú¬w°ê®a°ª¡A¹ï^°ê°ê¥Á«O°·ªA°È¨t²Î®£©È§Î¦¨¼ç¦b¦M¾÷¡A¤@¥¹Ãzµo®£©È·|ÆC¦¨§ó¦h¥»¥iÁקKªº¦º¤`ӮסC®ü¨U¼w§Æ±æ¬Ì]±µºØ²v¯à°÷¦A´£¤É¡A¥H¤Î¬°³ÌÃa±¡ªp¥´ºâ¡C
¥¼ÃÒ¬O§_½T¶E¼Æ¦r°ª¥ø¤¸¥û
^°ê©P¤@(18¤é)·s¼W49,156©v½T¶EӮסA¬O¤µ¦~7¤ë¥H¨Ó³Ì¦h¡A¹L¥h7¤Ñ¥§¡¯f¨Ò¸û¤§«e¤@©P¼W¥[16%¡A^°ê¨C¤é·s¼WӮתñ¨â©P±r«Þ¦bªñ4¸U°ª¦ì¡A»P¼Ú¬w±¡ªp~²§¡A¥O¤@¦V±j½Õ±µºØªº^°ê¬F©²¨üÀ£¡A¤]¥O¤H¼~¼{ÂåÀø¨t²ÎÀ£¤O¤@¦V¸û°ªªº¥V¤Ñ±¡ªp·|§ó®t¡C¼Æ¾ÚÅã¥Ü¡A^°ê½T¶E¼Æ¤W¤É·½¦Û¤¤¾Ç·P¬VªÌ¼W¥[¡A¦P®É³¡¤À¸û¤j¦~ÄÖ²Õ§Oªº·P¬V²v¤W¤É¡A·í¤¤¥]¬A®a¤¤¦³¤¤¾Ç¥Íªº¦~ÄÖ²Õ§O¡C¤J°|«¯g¤Î¦º¤`²v¤W¤É¨Ó¦Û¦~¬ö¸û¤j¤Î°ª¦M±Ú¸s¡A¥]¬A¬Ì]®Ä¥Î¶}©l¤U°ªº±Ú¸s¡C
º¬Û©²µo¨¥¤Hªí¥Ü¡A¤@ª½ª¾¹D¥¼¨Ó¼Æ¤ë·|¥Rº¡¬D¾Ô¡A¼È®É¬Ì±¡ªº¼Æ¾Ú»P¼Æ¤ë«eªº±Àºâ¤´¤jP§k¦X¡A¬Ì]¤´¬O^°ê¬F©²¨¾¬Ìªº²Ä¤@¹D¨¾½u¡AÁp¦P·sªvÀø¤èªk¡NÀË´ú¤Î¤½¦@°·±d«ØijÄ~Äò¨¾¬Ì¡C
¬ü°ê¹«~¤ÎÃĪ«ºÞ²z§½(FDA)«e§½ªø¤à¯S§Q¥¬(Scott Gottlieb)©P¤é¦bTwitterºÙ¡A^°ê¬Ì±¡¤Ï¼u¡AÅã¥Ü»Ýnºò«æ¬ã¨s¡uDelta+¡v¡A¥H¤F¸Ñ¥¦¬O§_§ó¨ã¶Ç¬V¤O¤Î¨ã¦³³¡¤ÀÁ×¹L§K¬Ì¨t²Îªº¯S©Ê¡C¤£¹L¤Ú¹p¯SºÙ¡AÁöµMAY.4.2¥O±¡úGÅܱo§xÃø¡A¦ý¼È®É¤£¯à§â³Ìªñ½T¶E¼Æ¦r°ª¥øÂk©S©óAY.4.2¡C¥L¤S©IÆ~¥~¬ÉÁקK¨Ï¥Î¡uDelta+¡v¦r²´¡A¦]³o·|¥O¤H²V²cAY.4.2©M¨ä¥LDelta¨ÈÅܺدf¬r¡C
AY.4.2¨â¬ðÅܯS¼x¤Þª`·N
AY.4.2¬O¥þ²y¦³¬ö¿ýªºDeltaÅܺØ45Ó¡u¤l¨t¡v¤§¤@¡A¥¦¾Ö¦³·P¬V¤HÃþ²ÓM¯f¬rªº´Æ¬ð³J¥Õ¤¤¨âÓ¬ðÅܯS¼x¡AºÙ¬°Y145H©MA222V¡A¦ý¥Ø«eÁÙ¤£²M·¡¥¦Ì¬°¦ó¥i¯à¥ODeltaÅܺاó¨ã¶Ç¬V©Ê¡C(ª÷¿Ä®É³ø/¸ô³zªÀ)